Anyone use this SERM?
If so, at what dosage - and did you have any succsess w/ gyno ??
08-10-2005, 09:07 AM #1
08-10-2005, 09:14 AM #2
Originally Posted by JoeD 4640[ANS Performance Representative]
- Join Date: Apr 2005
- Location: Chicago, Illinois, United States
- Posts: 15,870
- Rep Power: 16697
Disclaimer: The above post is my PERSONAL OPINION and DOES NOT REPRESENT the official position of any company or entity. It DOES NOT constitute medical advice.
08-10-2005, 09:18 AM #3
Raloxifene is a selective estrogen receptor modulator that produces both estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue. Because of its tissue selectivity, raloxifene may have fewer side effects than are typically observed with estrogen therapy. The most common adverse effects of raloxifene are hot flushes and leg cramps. The drug is also associated with an increased risk of thromboembolic events. The beneficial estrogenic activities of raloxifene include a lowering of total and low-density lipoprotein cholesterol levels and an augmentation of bone mineral density. Raloxifene has been labeled by the U.S. Food and Drug Administration for the prevention of osteoporosis. However, its effects on fracture risk and its ability to protect against cardiovascular disease have yet to be determined. Studies are also being conducted to determine its impact on breast and endometrial cancer reduction. (Am Fam Physician 1999;60:1131-9.)
seems like it could be used for pct, i dont htink it would make much of a difference because they both do the same thing for breast tissuePHD in bro science
08-10-2005, 09:19 AM #4
08-10-2005, 10:10 AM #5
08-10-2005, 10:47 AM #6
08-10-2005, 11:27 AM #7
08-10-2005, 12:18 PM #8
- Join Date: May 2005
- Location: Winston Salem, North Carolina, United States
- Age: 36
- Posts: 1,104
- Rep Power: 694
It is IMHO, the best non surgery option for people with gyno. It is specifically useful in pubertal gyno. You can read here:
If you were going to do a cycle to get rid of gyno, I would do an 8 week cycle of Raloxifene + atd. Since Raloxifene is a serm, using a high dose (which you will need) can lead to a huge rebound effect once you come off of it. Also, atd has shown at least some anecdotal evidence of helping cure gyno as well, so you should have great results. Try something like this.
week 1: 60mg Ralox + 50mg atd
week 2: 80mg Ralox + 75mg atd
week 3: 80mg Ralox + 75mg atd
week 4: 80mg Ralox + 75mg atd
week 5: 80mg Ralox + 50mg atd
week 6: 60mg Ralox + 50mg atd
week 7: 40mg Ralox + 50mg atd
week 8: 0mg Ralox + 25mg atd
If you need to run it longer, I suggest taking a break in weeks 9 and 10 from the atd. It isn't a good idea to run that longer than 8 weeks as it will slowly lower plasma estradiol levels.
As for pct, Ralox. would be a bad choice. It isn't nearly as good at stimulating lh as some of the other serms and suicide inhibitors. There is a good bit of research on this as well. FYI, I wouldn't go over 100mg per day at all.Mitotropin Unsponsored Log:
I hope you guys got permission to watch this:
Oh, just to explain, we use the word pimp alot. You gotta understand what pimp means. We pimp iron here, see, so it's not the traditional pimp word. We pimp iron, we're iron pimpers. All right? Holla, Pg's, Pimp Guards for life. West side
If you aint cheatin', you aint tryin'
Lightweight baby, nothin but a peanut
08-11-2005, 09:28 AM #9
08-11-2005, 09:32 AM #10
08-11-2005, 11:07 AM #11
08-11-2005, 11:09 AM #12
here we go;
For instance here is one where men received 120mg daily:
Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men.
Duschek EJ, Gooren LJ, Netelenbos C.
Department of Endocrinology, VU University Medical Centre, Amsterdam, The Netherlands.
OBJECTIVE: To explore effects on serum lipids, pituitary-gonadal axis, prostate and bone turnover of the administration of the mixed oestrogen agonist/antagonist raloxifene in healthy elderly men. PARTICIPANTS: Thirty healthy men aged 60-70 years randomly received raloxifene 120 mg/day (n=15) or placebo (n=15) for 3 months. MEASUREMENTS: In this double-blind, placebo-controlled study, serum gonadotrophins, sex hormones, prostate specific antigen (PSA), a marker of bone turnover, urinary hydroxyproline (OHPro) and cholesterol were measured at baseline and after 3 months. RESULTS: Raloxifene significantly increased serum concentrations of LH and FSH (by 29% and 21%), total testosterone (20%), free testosterone (16%) and bioavailable testosterone (not bound to sex hormone-binding globulin (SHBG; 20%). In parallel with testosterone, 17 beta-oestradiol also increased by 21%. SHBG increased by 7%. Total cholesterol (TChol) decreased significantly, from 5.7 to 5.5 mmol/l (P=0.03). Low-density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c) showed a trend to decrease. Overall, there was no change in urinary OHPro/creatinine ratio as a marker for bone resorption. However, the raloxifene-induced increases in both serum testosterone and 17 beta-oestradiol were significantly related to a lower OHPro/creatinine ratio. Total PSA increased by 17% without significant changes in free PSA or free/total PSA ratio. Participants reported no side effects and raloxifene was well tolerated. CONCLUSION: In healthy elderly man, raloxifene 120 mg/day for 3 months increased LH, FSH and sex steroid hormones. Potentially beneficial effects were the small but significant decrease in TChol and the trend towards a decrease in LDL-c. Negative effects were the trend towards a decrease in HDL-c and the significant increase in serum PSA. A decrease in markers of bone resorption during raloxifene treatment was found only in men with relatively high increases in serum testosterone and 17 beta-oestradiol. Overall, there were no clear beneficial effects of administration of raloxifene to ageing men in this preliminary investigation